Structural and functional assessment of macula in patients with high-risk Proliferative diabetic retinopathy submitted to Panretinal photocoagulation and associated Intravitreal Bevacizumab injections: A comparative, Randomised, controlled trial

Ophthalmologica

Volumn 230, Issue 1, 2013, Pages 1-8

  Preti, Rony Carlos ^a   Vasquez Ramirez, Lisa Mariel ^a   Ribeiro Monteiro, Mário Luiz ^a   Pelayes, David E ^b,c   Takahashi, Walter Yukihiko ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Av Ramalho Ortigão ^*  (Brazil)

^c DEPARTAMENTO DE CIENCIAS NATURALES Y ANTROPOLOGÍA   (Argentina)

Author keywords

Diabetic macular oedema; High risk proliferative diabetic retinopathy; Intravitreal bevacizumab injections; Panretinal photocoagulation

Indexed keywords

BEVACIZUMAB; ANTIBIOTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERVENTION STUDY; LASER COAGULATION; MALE; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA LUTEA; RETINAL THICKNESS; TREATMENT OUTCOME; VISUAL ACUITY; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; CLINICAL PROTOCOL; FLUORESCENCE ANGIOGRAPHY; FUNCTIONAL ASSESSMENT; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; KOLMOGOROV SMIRNOV TEST; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MEDICAL HISTORY; THROMBOEMBOLISM;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; LIGHT COAGULATION; MACULA LUTEA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84879839114     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000348605     Document Type: Article

References (39)

1. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(5 suppl): 766-785
2. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991; 98(5 suppl):741-756
3. Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol 1976; 81: 383-396
4. Doft BH, Blankenship GW: Single versus multiple treatment sessions of argon laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1982; 89: 772-779 (Pubitemid 12039443)
5. Ferris FL 3rd, Podgor MJ, Davis MD: Macular edema in Diabetic Retinopathy Study patients. Diabetic Retinopathy Study Report Number 12. Ophthalmology 1987; 94: 754-760 (Pubitemid 17123153)
6. McDonald HR, Schatz H: Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1985; 92: 388-393 (Pubitemid 15099102)
7. McDonald HR, Schatz H: Macular edema following panretinal photocoagulation. Retina 1985; 5: 5-10 (Pubitemid 15120379)
8. Higgins KE, Meyers SM, Jaffe MJ, Roy MS, de Monasterio FM: Temporary loss of foveal contrast sensitivity associated with panretinal photocoagulation. Arch Ophthalmol 1986; 104: 997-1003 (Pubitemid 16062065)
9. Nonaka A, Kiryu J, Tsujikawa A, Yamashiro K, Nishijima K, Kamizuru H, et al: Inflammatory response after scatter laser photocoagulation in nonphotocoagulated retina. Invest Ophthalmol Vis Sci 2002; 43: 1204-1209 (Pubitemid 34258294)
10. Tsujikawa A, Kiryu J, Dong J, Yasukawa T, Suzuma I, Takagi H, et al: Quantitative analysis of diabetic macular edema after scatter laser photocoagulation with the scanning retinal thickness analyzer. Retina 1999; 19: 59-64 (Pubitemid 30387542)
11. Funatsu H, Yamashita H, Ikeda T, Mimura T, Shimizu E, Hori S: Relation of diabetic macular edema to cytokines and posterior vitreous detachment. Am J Ophthalmol 2003; 135: 321-327 (Pubitemid 36279518)
12. Del Maschio A, Zanetti A, Corada M, Rival Y, Ruco L, Lampugnani MG, et al: Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions. J Cell Biol 1996; 135: 497-510 (Pubitemid 26359342)
13. Brooks HL Jr, Caballero S Jr, Newell CK, Steinmetz RL, Watson D, Segal MS, et al: Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabe tic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 2004; 122: 1801-1807 (Pubitemid 39602140)
14. Shimura M, Yasuda K, Nakazawa T, Kano T, Ohta S, Tamai M: Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003; 110: 2386-2394 (Pubitemid 37485170)
15. Classification of diabetic retinopathy from fluorescein angiograms: ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(5 suppl):807-822
16. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796-1806
17. Lee CM, Olk RJ: Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991; 98: 1594-1602
18. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342 (Pubitemid 38702844)
19. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al: Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005 (Pubitemid 44973218)
20. Michaelides M, Kaines A, Hamilton RD, Fraser- Bell S, Rajendram R, Quhill F, et al: A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117: 1078 e2-1086 e2
21. Cho WB, Oh SB, Moon JW, Kim HC: Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 2009; 29: 516-522
22. Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H: Bevacizumab- augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked cli nical trial. Eur J Ophthalmol 2008; 18: 263-269 (Pubitemid 351692187)
23. Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, Jorge R: Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008; 86: 385-389
24. Shin YW, Lee YJ, Lee BR, Cho HY: Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy. Korean J Ophthalmol 2009; 23: 266-272
25. Mason JO 3rd, Yunker JJ, Vail R, McGwin G Jr: Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy. Retina 2008; 28: 1319-1324
26. Costa RA, Skaf M, Melo LA Jr, Calucci D, Cardillo JA, Castro JC, et al: Retinal assessment using optical coherence tomography. Prog Retin Eye Res 2006; 25: 325-353 (Pubitemid 43782816)
27. Frank RN, Schulz L, Abe K, Iezzi R: Temporal variation in diabetic macular edema measured by optical coherence tomography. Ophthalmology 2004; 111: 211-217 (Pubitemid 38183216)
28. Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris F, et al: Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2010; 117: 946-953
29. Aiello LP, Brucker AJ, Chang S, Cunningham ET Jr, D'Amico DJ, Flynn HW Jr, et al: Evolving guidelines for intravitreous injections. Retina 2004; 24(5 suppl):S3-S19 (Pubitemid 39391785)
30. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No 3. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin 1987; 27: 254-264
31. Arevalo JF, Garcia-Amaris RA: Intravitreal bevacizumab for diabetic retinopathy. Curr Diabetes Rev 2009; 5: 39-46
32. Maia OO Jr, Takahashi BS, Costa RA, Scott IU, Takahashi WY: Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: oneyear results of a randomized clinical trial. Am J Ophthalmol 2009; 147: 291 e2-297 e2
33. Sugita T, Kondo M, Piao CH, Ito Y, Terasaki H: Correlation between macular volume and focal macular electroretinogram in patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci 2008; 49: 3551-3558
34. Lima-Gómez V, Blanco-Hernández DM: Disparity between foveal thickness and macular volume in diabetic macular edema. Cir Cir 2012; 80: 25-30
35. Otani T, Yamaguchi Y, Kishi S: Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina 2010; 30: 774-780
36. Nasrallah FP, Jalkh AE, Van Coppenolle F, Kado M, Trempe CL, McMeel JW, et al: The role of the vitreous in diabetic macular edema. Ophthalmology 1988; 95: 1335-1339
37. Hikichi T, Fujio N, Akiba J, Azuma Y, Takahashi M, Yoshida A: Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. Ophthalmology 1997; 104: 473-478 (Pubitemid 27120303)
38. Arend O, Wolf S, Harris A, Reim M: The relationship of macular microcirculation to visual acuity in diabetic patients. Arch Ophthalmol 1995; 113: 610-614
39. Bird AC, Weale RA: On the retinal vasculature of the human fovea. Exp Eye Res 1974; 19: 409-417.